Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2005
04/14/2005CA2540671A1 Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
04/14/2005CA2540670A1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient
04/14/2005CA2527617A1 Benzo-(4,5)-thieno-(2,3d)-pyrimidin-4-ones and their use in the treatment or prevention of a steroid hormone dependent disease or disorder
04/13/2005EP1522542A1 Therapeutic or preventive agent for nausea/vomiting
04/13/2005EP1522539A1 Crystalline composition containing escitalopram
04/13/2005EP1522314A1 Remedies for diseases caused by vascular contraction or dilation
04/13/2005EP1522305A1 Combinations of sumatriptan with a cyclooxygenase II inhibitor
04/13/2005EP1521824A2 Nucleic acid-associated proteins
04/13/2005EP1521822A2 Protein modification and maintenance molecules
04/13/2005EP1521779A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same
04/13/2005EP1521757A1 Novel tricyclic spiropiperidines or spiropyrrolidines
04/13/2005EP1521756A1 Hetero-cyclicaly substituted imidazotriazines
04/13/2005EP1521744A1 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists
04/13/2005EP1521740A2 Probucol derivatives
04/13/2005EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
04/13/2005EP1521599A2 Absorption enhancing agent
04/13/2005EP1521594A2 Endogenous retrovirus polypeptides linked to oncogenic transformation
04/13/2005EP1521593A2 Transdermal botulinum toxin compositions
04/13/2005EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
04/13/2005EP1521583A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives
04/13/2005EP1521580A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists
04/13/2005EP1521575A1 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
04/13/2005EP1521523A2 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
04/13/2005EP1289955B1 Piperidines for use as orexin receptor antagonists
04/13/2005EP1246827B1 New polymorphic forms of olanzapine
04/13/2005EP1244641B1 Thiazolyl amide derivatives
04/13/2005EP1212060B1 Use of nicotine or derivatives thereof and l-dopa in a medicine for treating neurological diseases, in particular parkinson disease
04/13/2005EP1212052B1 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
04/13/2005EP1105728B1 Modulating multiple lineage kinase proteins
04/13/2005EP1090105B1 Non-embryonic ependymal neural stem cells and method for their isolation
04/13/2005EP0871488B1 Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agonist and a kappa-2 opioid agonist
04/13/2005CN1606694A Methods for monitoring and treating amyotrophic lateral sclerosis
04/13/2005CN1606563A Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
04/13/2005CN1606560A Novel benzothiazine and benzothiadiazine derivatives, method for preparing same, their use and pharmaceutical compositions containing same
04/13/2005CN1606559A Novel benzothiazine and benzothiadiazine derivatives, method for preparing same, their use and pharmaceutical compositions containing same
04/13/2005CN1606556A Triazolo-quinolin derivatives useful as adenosine receptor ligands
04/13/2005CN1606555A Imidazoquinoline derivatives
04/13/2005CN1606554A Beta-lactamyl vasopressin v1aantagonists
04/13/2005CN1606552A Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
04/13/2005CN1606550A Benzothia(dia)zine derivatives and their use as AMPA modulators
04/13/2005CN1606548A Aryloxyphenyl and arylsulfanylphenyl piperazine derivatives
04/13/2005CN1606545A Pyrrolidine and piperidine derivates as nk1 antagonists
04/13/2005CN1606544A Bicyclic compound
04/13/2005CN1606451A Remedies and/or preventives for conformational diseases
04/13/2005CN1606446A Method for preventing and treating communicable diseases and other diseases using monosaccharides and disaccharides
04/13/2005CN1606444A Inhibitors of human phosphatidyl-inositol 3-kinase delta
04/13/2005CN1606442A Treatments for restless legs syndrome
04/13/2005CN1606440A Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them
04/13/2005CN1606436A Compounds and methods of treating transplant rejection
04/13/2005CN1606435A Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
04/13/2005CN1606427A Stable surfactant compositions for suspending components
04/13/2005CN1605294A Compound tobacco addict controlling plaster and its preparation method
04/13/2005CN1196785C Beta-amyloid peptdie-binding proteins and polynucleotides encoding the same
04/13/2005CN1196784C Promoter of human endoglin gene and its use
04/13/2005CN1196708C Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols
04/13/2005CN1196682C 4-pyridinyl-N-acyl-L-phenylalanines
04/13/2005CN1196680C Modulators of dopamine neurotransmission
04/13/2005CN1196671C Mono-and-disubstituted 2-pyrolyl gamma-aminobutric acids
04/13/2005CN1196488C Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
04/13/2005CN1196486C Ziprasidone suspension liquid
04/13/2005CN1196482C Use of anticonvulsant derivatives for treating bulimia nervosa
04/13/2005CN1196481C Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
04/13/2005CN1196477C Pharmaceutical compsition for oral delivery
04/12/2005US6878823 Substituted and unsubstitued 9-arylsulfone- 1,2,3,4,5,6-hexahydroazepino (4,5-b) indoles are useful in treatment of depression, obesity and other central nervous system disorders
04/12/2005US6878743 Controlling apoptosis; central nervous system disorders
04/12/2005US6878742 Alzheimer's disease; Down's syndrome
04/12/2005US6878740 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds
04/12/2005US6878736 Histamine H3 receptor ligands
04/12/2005US6878732 5,7-diazaspiro(3.4)octane and -octene derivatives; treating diseases including emesis, depression, anxiety and cough
04/12/2005US6878726 For therapy and prophylaxis inflammation, other inflammation associated disorders, such as arthritis, neurodegeneration and colon cancer, in mammals, dogs, cats or livestock animals
04/12/2005US6878721 Beta2-adrenoceptor agonists
04/12/2005US6878718 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
04/12/2005US6878709 Treating acute and chronic inflammatory disorders and cancer.
04/12/2005US6878708 Imidazotriazinones and the use thereof
04/12/2005US6878701 Potassium channel blocking agents
04/12/2005US6878690 Compounds and methods
04/12/2005US6878529 Compounds for the treatment of sexual dysfunction
04/12/2005US6878522 Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
04/12/2005CA2385854C Formulation for menopausal women
04/12/2005CA2362336C Anticonvulsant derivatives useful in treating essential tremor
04/12/2005CA2356065C Phenoxyphenylheterocycle derivatives as ssris
04/12/2005CA2293247C 4-phenylpiperidine compounds
04/12/2005CA2267994C Truncated platelet-activating factor acetylhydrolase
04/12/2005CA2250704C Glial cell line-derived neurotrophic factor receptor
04/12/2005CA2194471C Bis-piperidinyl non-peptidyl tachykinin receptor antagonist
04/12/2005CA2128380C 4-aryloxy- and 4-arylthiopiperidine derivatives
04/10/2005CA2702138A1 Sustained-release tramadol formulations with 24-hour clinical efficacy
04/07/2005WO2005031347A1 Methods
04/07/2005WO2005030778A1 Ligands
04/07/2005WO2005030777A1 Non-amide nonanes
04/07/2005WO2005030773A1 Novel pyrazolopyrimidine derivatives
04/07/2005WO2005030771A1 Imidazopyridine-derivatives as inductible no-synthase inhibitors
04/07/2005WO2005030770A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors
04/07/2005WO2005030769A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors
04/07/2005WO2005030768A1 Imidazo(4,5-b)pyridine-derivatives as inducible no-synthase inhibitors
04/07/2005WO2005030763A1 Benzisoxazoles
04/07/2005WO2005030762A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
04/07/2005WO2005030761A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
04/07/2005WO2005030755A1 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
04/07/2005WO2005030754A1 Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity
1 ... 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 ... 1833